Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB1211 and Pembrolizumab in Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
NCT05913388Phase 2Active, not recruiting
- Start
- Feb 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selvigaltin in melanoma, head and neck squamous cell carcinoma (HNSCC). Started Feb 2024; status: active, not recruiting.
02
Drugs
selvigaltin
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05913388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05913388.